Myeloid and lymphoid neoplasm with eosinophilia and abnormalities of PDGFRB presenting as congestive heart failure and hypereosinophilia
Allergy, Asthma & Respiratory Disease
;
: 232-236, 2017.
Article
in Korean
| WPRIM
| ID: wpr-49040
ABSTRACT
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by persistent hypereosinophilia with the evidence of organ dysfunction caused by eosinophilic involvement. HES can be induced by various secondary causes, including helminthic infections, adverse drug reactions, and allergic diseases. Primary/clonal bone marrow disease, including genetic mutations in platelet driven growth factor receptor alpha (PDGFRA), platelet driven growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor 1 (FGFR1) could be its causes. Although corticosteroids are the mainstay of therapy in confirmed HES, imatinib is considered a definitive treatment for HES with these mutations. However, there have been few reports about HES with these genetic mutations in Korea. Here, we report a patient who presented with sudden onset of congestive heart failure and hypereosinophilia, proved to have PDGFRB rearrangement, and was controlled successfully with imatinib after left ventricle thrombectomy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Platelets
/
Bone Marrow Diseases
/
Thrombectomy
/
Adrenal Cortex Hormones
/
Hypereosinophilic Syndrome
/
Estrogens, Conjugated (USP)
/
Receptor, Platelet-Derived Growth Factor beta
/
Drug-Related Side Effects and Adverse Reactions
/
Eosinophilia
/
Eosinophils
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Allergy, Asthma & Respiratory Disease
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS